Abstracts tagged "Psoriatic arthritis"

Abstract Number: 2891 • 2015 ACR/ARHP Annual Meeting
Assessment of Disability Levels in a Cohort of 1,489 Patients with Active Psoriatic Arthritis, and the Effect of Apremilast Treatment: Pooled Data from Three Phase III, Randomized, Controlled Trials
Philip J. Mease¹, Jürgen Wollenhaupt², Stephen Hall³, Filip van Den Bosch⁴, Eric Lespessailles⁵, Melissa McIlraith⁶, Lichen Teng⁶ and Christopher J. Edwards⁷, ¹Rheumatology Research, Swedish Medical Center, Seattle, WA, ²Schön Klinik Hamburg Eilbek, Hamburg, Germany, ³Monash University, CabriniHealth, Melbourne, Australia, ⁴Rheumatology, Ghent University Hospital, VIB, Ghent, Belgium, ⁵University of Orléans, Orléans, France, ⁶Celgene Corporation, Warren, NJ, ⁷University Hospital Southampton, Southampton, United Kingdom
Background/Purpose: PsA, a chronic systemic inflammatory disease, reduces physical function and QOL. Treatment improves/maintains functionality. PALACE 1-3 compared apremilast (APR) efficacy/safety with placebo (PBO) in…
Abstract Number: 702 • 2015 ACR/ARHP Annual Meeting
Is Skin Disease More Important to Patients or Physicians in the Assessment of Disease Activity in Psoriatic Arthritis?
Dalton Sholter¹, Proton Rahman², J Antonio Avina-Zubieta³, John Kelsall⁴, Regan Arendse⁵, Majed M. Khraishi⁶, S Shaikh⁷, William G. Bensen⁸, Emmanouil Rampakakis⁹, John S. Sampalis¹⁰, Francois Nantel¹¹, May Shawi¹², Susan Otawa¹³, Cathy Tkaczyk¹³ and Allen J Lehman¹², ¹Rheumatology Associates, Edmonton, AB, Canada, ²Rheumatology, St. Clare's Mercy Hospital, St. John's, NF, Canada, ³Medicine, University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada, ⁴Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁵University of Saskatchewan, Saskatoon, SK, Canada, ⁶Nexus Clinical Research, St Johns, NF, Canada, ⁷Niagara Peninsula Arthritis Centre, Hamilton, ON, Canada, ⁸St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁹JSS Medical Research, St-Laurent, QC, Canada, ¹⁰McGill University, Montreal, QC, Canada, ¹¹19 Green belt Dr, Janssen Inc., Toronto, ON, Canada, ¹²Janssen Inc., Toronto, ON, Canada, ¹³Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Patient (PtGA) and physician (MDGA) global assessment of disease activity are standard outcome measures used in clinical practice and research to ascertain patient and…
Abstract Number: 3117 • 2015 ACR/ARHP Annual Meeting
Under-Treatment of Cardiovascular Risk Factors in Patients with Psoriatic Disease – an International Multicentre Study
Lihi Eder¹, Vinod Chandran¹, Cheryl Rosen², Jan Dutz³, James T. Elder⁴, Proton Rahman⁵, Christopher T. Ritchlin⁶, Francisco A. Tausk⁷, Sherry Rohekar⁸, Richard Hayday⁹, Snezana Barac¹⁰, Devy Zisman¹¹, Joy Feld¹² and Dafna D. Gladman¹, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Dermatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³University of British Columbia, Vancouver, BC, Canada, ⁴University of Michigan Medical School, Ann Arbor, MI, ⁵Computer Sciences, Memorial University of Newfoundland, St. John's, NF, Canada, ⁶Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY, ⁷University of Rochester Medical Center, Rochester, NY, ⁸Western University, London, ON, Canada, ⁹University of Manitoba, Winnipeg, MB, Canada, ¹⁰Winnipeg Clinic, Winnipeg, MB, Canada, ¹¹Rheumatology Unit, Carmel Medical Center, Haifa, Israel, ¹²Carmel Medical Center, Haifa, Israel
Background/Purpose: Cardiovascular risk in patients with psoriatic disease is partly attributed to the high prevalence of traditional cardiovascular risk factors in these patients. This study…
Abstract Number: 1057 • 2015 ACR/ARHP Annual Meeting
Are Ankylosing Spondylitis, Psoriatic Arthritis and Undifferentiated Spondylarthritis Associated with an Increased Risk of Cardiovascular Disease?
Karin Bengtsson¹, Helena Forsblad-d'Elia², Elisabeth Lie¹, Eva Klingberg¹, Mats Dehlin¹, Sofia Exarchou³, Ulf Lindström¹, Johan Askling⁴ and Lennart TH Jacobsson¹, ¹Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ²Departments of Public Health and Clinical Medicine, Rheumatology, Umeå University, Umeå, Sweden, ³Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁴Clinical Epidemiology Unit and Rheumatology Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden
Background/Purpose: It is unclear whether and to what extent different phenotypes of spondylarthritis (SpA) are associated with an increased risk of cardiovascular events such as…
Abstract Number: 3207 • 2015 ACR/ARHP Annual Meeting
Axial Disease in Psoriatic Arthritis: A Clinical and Radiographic Comparison with Ankylosing Spondylitis
Deepak R. Jadon¹, Raj Sengupta¹, Alison L Nightingale², Mark Lindsay³, Eleanor Korendowych¹, Graham Robinson⁴, Amelia Jobling⁵, Gavin Shaddick⁶, Anne Barton⁷ and Neil J. McHugh⁸, ¹Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, ³Pharmacy & Pharmacology, University of Bath, Bath, United Kingdom, ⁴Royal United Hospital, Bath, United Kingdom, ⁵Mathematical Sciences, University of Bath, Bath, United Kingdom, ⁶Department of Mathematics, University of Bath, Bath, United Kingdom, ⁷Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University Of Manchester, Manchester, United Kingdom, ⁸Rheumatology, Royal National Hospital for Rheumatic Diseases, Upper Borough Walls, United Kingdom
Background/Purpose: Little is known of the characteristics of psoriatic spondyloarthritis (PsSpA). A study was conducted to determine the: (i) prevalence of PsSpA in a psoriatic…
Abstract Number: 1059 • 2015 ACR/ARHP Annual Meeting
Increased Risk of Atrioventricular Block, Atrial Fibrillation and Pacemaker Implantation in Ankylosing Spondylitis, Undifferentiated Spondylarthritis and Psoriatic Arthritis Compared to the General Population
Karin Bengtsson¹, Helena Forsblad-d'Elia², Elisabeth Lie¹, Eva Klingberg¹, Mats Dehlin¹, Sofia Exarchou³, Ulf Lindström¹, Johan Askling⁴ and Lennart TH Jacobsson¹, ¹Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ²Departments of Public Health and Clinical Medicine, Rheumatology, Umeå University, Umeå, Sweden, ³Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁴Clinical Epidemiology Unit and Rheumatology Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden
Background/Purpose: There is a known association between conduction disturbances and ankylosing spondylitis (AS). The risk of conduction disturbances in other phenotypes of spondylarthritis (SpA) is…
Abstract Number: 1629 • 2015 ACR/ARHP Annual Meeting
Non-Interventional Clinical Study Investigating the Use of Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis in Germany – 3rd Interim Analysis
Matthias H. Thomas¹, Klaus Krüger², Pee Aries³, Martin Bohl-Buehler⁴, Jan Brandt-Juergens⁵, Verena Rickert⁶ and Siegfried Wassenberg⁷, ¹Medical Affairs, MSD Sharp & Dohme GmbH, Bünde, Germany, ²Praxiszentrum St. Bonifatius, München, Germany, ³Rheumatologie im Struenseehaus, Hamburg, Germany, ⁴Friedrich-Ebert-Str. 35, Rheumahaus, Potsdam, Germany, ⁵Praxis Brandt-Juergens/Karberg, Berlin, Germany, ⁶Medical Affairs, MSD Sharp&Dohme GmbH, Haar, Germany, ⁷Fachkrankenhaus, Ratingen, Germany
Background/Purpose: Golimumab (GOL) has shown its efficacy and safety in various randomized clinical trials with accurately selected patients. Data from daily clinical practice in Germany…
Abstract Number: 1715 • 2015 ACR/ARHP Annual Meeting
Sensivity and Specificity of Clinical Criteria to Identify Patients in Ultrasound Remission in Psoriatic Arthritis
Brigitte Michelsen¹, Andreas P Diamantopoulos², Hilde Berner Hammer³, Arthur Kavanaugh⁴ and Glenn Haugeberg^1,5,6, ¹Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ²Haugesund Rheumatism Hospital, Haugesund, Norway, ³Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴University of California, San Diego School of Medicine, LaJolla, CA, ⁵Rheumatology, The Norwegian University of Science and Technology, Trondheim, Norway, ⁶Rheumatology, Martina Hansens Hospital, Gjettum, Norway
Background/Purpose: To date, although several have been proposed, there are no validated remission criteria in psoriatic arthritis (PsA). Validated criteria for minimal disease activity (MDA) in…
Abstract Number: 37 • 2015 ACR/ARHP Annual Meeting
Cardiovascular Disease in Immune-Mediated Inflammatory Diseases: Cross Sectional Analysis of the Influence of Demographic and Traditional Cardiovascular Risk Factors
Luis Rodriguez-Rodriguez^1,2, Pedro P Perrotti³, Adrìa Aterido³, Jesús Tornero⁴, Carlos Ferrandiz⁵, Juan D. Cañete⁶, Antonio Fernandez-Nebro⁷, Javier P Gisbert⁸, Eugeni Domènech^9,10, María López-Lasanta³, Sara Marsal³, Benjamín Fernández-Gutiérrez^1,11 and IMID Consortium, ¹Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, ²Department of Rheumatology, Hospital Clinico San Carlos, Madrid, Spain, ³Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ⁴Rheumatology Department, Hospital Universitario Guadalajara, Guadalajara, Spain, ⁵Dermatology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁶Rheumatology, Hospital Clinic and IDIBAPS, Barcelona, Spain, ⁷Rheumatology, Hospital Regional Carlos Haya, Biomedical Research Institute of Malaga (IBIMA), Malaga, Spain, ⁸Gastroenterology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ⁹Gastroenterology & Hepatology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹⁰CIBERehd, Madrid, Spain, ¹¹Rheumatology, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose : Our aim was 1) to analyze the association between demographic and traditional cardiovascular risk factors (CVRF) and cardiovascular disease (CVD) in subjects affected…
Abstract Number: 1726 • 2015 ACR/ARHP Annual Meeting
Reliability of Radiographic Assessment of Psoriatic Arthritis Mutilans
Dennis Wong¹, Ker-Ai Lee², Richard J. Cook³, Dafna Gladman⁴, Lihi Eder⁴ and Vinod Chandran⁴, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ³Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ⁴Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis mutilans (PsAM) is the most severe form of Psoriatic arthritis (PsA). Research on PsAM has been hampered by the lack of an…
Abstract Number: 103 • 2015 ACR/ARHP Annual Meeting
Axial Disease in Psoriatic Arthritis: Genetic Biomarkers of Psoriatic Spondyloarthritis
Deepak R. Jadon¹, John Bowes², Anne Barton³, Raj Sengupta¹, Alison L Nightingale⁴, Mark Lindsay⁵, Eleanor Korendowych¹, Graham Robinson⁶ and Neil J. McHugh⁷, ¹Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Arthritis Research UK Centre for Genetics and Genomics, The University of Manchester, Centre for Musculoskeletal Research, Manchester, United Kingdom, ³Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University Of Manchester, Manchester, United Kingdom, ⁴Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, ⁵Pharmacy & Pharmacology, University of Bath, Bath, United Kingdom, ⁶Royal United Hospital, Bath, United Kingdom, ⁷Rheumatology, Royal National Hospital for Rheumatic Diseases, Upper Borough Walls, United Kingdom
Background/Purpose: A lack of well-characterised clinical cohorts has impeded research of the genetics of axial disease in psoriatic arthritis (PsA). We sought to determine genetic…
Abstract Number: 2495 • 2015 ACR/ARHP Annual Meeting
Tele-Monitoring of Disease Activity in Rheumatoid Arthritis and Psoriatic Arthritis
Alexander Langer¹ and Hans-Eckhard Langer², ¹Department of Computer Science, RWTH Aachen University, Aachen, Germany, ²RHIO (Rheumatology, Immunology, and Osteology), Duesseldorf, Germany
Background/Purpose: There is evidence that tight control of rheumatoid arthritis improves outcome. In daily practice this aim is constricted by logistic limitations such as a…
Abstract Number: 165 • 2015 ACR/ARHP Annual Meeting
Validation of a New Ultrasound Criteria for Subclinical Synovitis in Chronic Inflammatory Polyarthritis
Julio Ramírez¹, Jose Inciarte-Mundo², Andrea Cuervo¹, Virginia Ruiz-Esquide², M. Victoria Hernández³, Raimon Sanmarti² and Juan D. Cañete², ¹Arthritis Unit. Rheumatology, Hospital Clínic of Barcelona, Barcelona, Spain, ²Rheumatology Department, Hospital Clinic i Provincial, Barcelona, Spain, ³Arthritis Unit, Rheumatology, Hospital Clinic, Barcelona, Spain
Background/Purpose: We have previously reported that patients with subclinical synovitis defined by synovial hypertrophy grade >2 (SH>2) plus power Doppler (PD) signal had higher disease…
Abstract Number: 2839 • 2015 ACR/ARHP Annual Meeting
Disease Activity and Safety during Long-Term (104-Week) Treatment with Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension
Christopher J. Edwards¹, Francisco J. Blanco², Jeffrey Crowley³, ChiaChi Hu⁴, Kamal Shah⁴ and Charles A. Birbara⁵, ¹University Hospital Southampton, Southampton, United Kingdom, ²Osteoarticular and Aging Research Lab. Proteomics Unit - Associated Node to ProteoRed, Rheumatology Division, Proteomics Group-ProteoRed/ISCIII, INIBIC-CHUAC, A Coruña, Spain, ³Bakersfield Dermatology, Bakersfield, CA, ⁴Celgene Corporation, Warren, NJ, ⁵University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, acts to regulate immune responses in psoriatic arthritis (PsA). PALACE 3 compared the efficacy and safety of…
Abstract Number: 591 • 2015 ACR/ARHP Annual Meeting
Rosuvastatin Improves Endothelial Function in Patients with Inflammatory Joint Diseases, Longitudinal Associations with Atherosclerosis and Arteriosclerosis
Eirik Ikdahl¹, Jonny Hisdal², Silvia Rollefstad¹, Inge C Olsen³, Tore K. Kvien⁴, Terje R. Pedersen⁵ and Anne Grete Semb⁶, ¹Preventive Cardio-Rheuma Clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Section of Vascular Investigations, Oslo University Hospital Aker, Oslo, Norway, ³Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁵Department of Preventive Cardiology, Ullevaal University Hospital, Oslo, Norway, ⁶Preventive Cardio-Rheuma clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Endothelial dysfunction is an early step in the formation of atherosclerotic lesions and can be quantified by the degree of flow mediated vasodilation (FMD)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].